Sandwell and West Birmingham Hospital Trusts, Birmingham, UK.
Mayo Clinic Medical Scientist Training Program, Mayo Clinic Alix School of Medicine and Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.
Int J Dermatol. 2019 Jul;58(7):856-860. doi: 10.1111/ijd.14392. Epub 2019 Mar 7.
The occurrence of chemotherapy-related adverse cutaneous reactions in the setting of capillary leak syndrome (CLS) is quite rare. Our objective was to identify the type of skin reactions associated with CLS.
Leukemia or hematopoietic stem cell transplant patients between January 2010 and December 2017 were identified, and medical records were reviewed for a dermatology consultation occurring concomitantly with CLS.
Five patients were identified, two with a diagnosis of toxic erythema of chemotherapy (TEC) and three others with a skin diagnosis of toxic epidermal necrolysis (TEN). Pathology of all patients was available for clinical-pathologic confirmation.
Although TEC is generally self-limited, both TEC and TEN can present with severe adverse skin manifestations during CLS secondary to toxicity from chemotherapy.
在毛细血管渗漏综合征（CLS）的情况下，发生化疗相关的皮肤不良反应非常罕见。我们的目的是确定与 CLS 相关的皮肤反应类型。
回顾 2010 年 1 月至 2017 年 12 月期间的白血病或造血干细胞移植患者，并对同时伴有 CLS 的皮肤科会诊的病历进行审查。
确定了 5 例患者，其中 2 例诊断为化疗药物毒性红斑（TEC），另外 3 例诊断为中毒性表皮坏死松解症（TEN）。所有患者均有可供临床病理确认的病理。
虽然 TEC 通常是自限性的，但 TEC 和 TEN 都可因化疗毒性而在 CLS 期间出现严重的皮肤不良反应。
